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ABSTRACT
We prospectively evaluated the prognostic significance of occult tumor cells (OTCs) contaminating the
peripheral blood progenitor cell apheresis products of patients with advanced breast cancer receiving high-
dose chemotherapy. Immunocytochemistry of peripheral blood progenitor cells was performed in 242 patients
with high-risk primary breast cancer (HRPBC) and in 111 patients with metastatic breast cancer (MBC). OTCs
were detected in 6.6% of HRPBC patients and in 16.2% of MBC patients (P  .005). In HRPBC, OTCs
correlated with worse prognostic scores and larger tumor sizes, but not with axillary nodal status, hormone
receptors, or HER2. In the MBC group, OTCs correlated with bone marrow involvement and with disease
status at transplantation. The number of apheresis procedures was not associated with the risk of contamina-
tion. In HRPBC patients, at a median follow-up of 7 years (range, 1.5-11 years), the presence of OTCs
correlated with worse event-free survival (P  .007) and overall survival (P  .002). In the MBC group, OTCs
correlated with worse event-free survival (P  .04), but not overall survival (P  .2). In multivariate analyses,
the presence of OTCs had an independent adverse effect on outcome in HRPBC, but not MBC. Our
observations imply a direct role of OTCs in posttransplantation relapse in HRPBC.
© 2004 American Society for Blood and Marrow Transplantation
KEY WORDS
Tumor contamination ● Apheresis products ● High-dose chemotherapy ● Advanced breast
cancer
r
d
a
a
t
b
o
p
o
s
c
(NTRODUCTION
The use of high-dose chemotherapy (HDC) with
utologous hematopoietic progenitor cell support has
een investigated for advanced breast cancer with the
oal of improving the long-term outcome of patients
ith high-risk primary breast cancer (HRPBC), de-
ned as extensive (4 positive nodes) axillary involve-
ent, inﬂammatory breast carcinoma (IBC), or met-
static breast cancer (MBC). HDC has been compared
ith standard-dose chemotherapy (SDC) in numerous
andomized trials for HRPBC or MBC, most of which
ave been analyzed only in preliminary fashion at a
elatively short follow-up (see review [1]). The most s
B&MTecent Cochrane reviews of their pooled data have
etected early signiﬁcant event-free survival (EFS)
dvantages in favor of HDC in both settings [2,3],
lbeit without overall survival (OS) differences at the
ime of the analysis.
Potential reasons for failure of HDC to eradicate
reast cancer include an insufﬁcient antitumor effect
f the high-dose regimen or reinfusion of a stem cell
roduct contaminated with tumor cells. Detection of
ccult tumor cells (OTCs) in bone marrow (BM) or
tem cell products has largely relied on immunocyto-
hemistry (ICC) [4] or polymerase chain reaction
PCR)–based techniques [5,6], which target molecules
uch as cytokeratins that are present in epithelial cells
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4nd not in hematopoietic precursors [7]. Of note, a
igh incidence of false-positive results has been re-
orted with PCR [8].
Multiple studies have demonstrated an adverse
ndependent prognostic effect of occult metastases in
he BM (detected with ICC) in stage I to III patients
reated with SDC [9-17]. In the HDC setting, tumor
ell contamination of pelvic BM harvests has been
ssociated with worse outcome, both in HRPBC [18-
0] and MBC [18,21].
Apheresis of peripheral blood progenitor cells
PBPCs) after mobilization with granulocyte colony-
timulating factor (G-CSF), with or without chemo-
herapy, has a lower incidence of contaminated prod-
cts than harvests of BM [5,22]. Most prognostic
tudies of ICC-detected OTCs in the apheresis prod-
cts of HRPBC patients have been limited by a small
ample size, a short follow-up, and an absence of
ultivariate analyses. Some studies [23-26], but not
thers [27-29], suggest an adverse prognostic effect in
his population. Studies in MBC patients also show
ontradictory results [27,30,31]. Thus, there are cur-
ently no ﬁrm conclusions about the prognostic value
f and potential role for OTCs in posttransplantation
elapse in either setting. In this article, we report a
ong-term prognostic analysis of prospective ICC
valuations of the PBPC apheresis products of 242
RPBC and 111 MBC patients who received identi-
al HDC.
ATIENTS AND METHODS
atient Population
We evaluated breast cancer patients who under-
ent apheresis of PBPCs after enrollment in prospec-
ive research trials of high-dose cyclophosphamide,
isplatin, and carmustine (the STAMP-I regimen) at
he University of Colorado Bone Marrow Transplant
rogram between 1990 and 2001. Trials for HRPBC
ncluded phase II and III studies for patients with 4 to
positive axillary nodes [32], 10 positive nodes [33],
r IBC [34]. MBC patients were enrolled in phase II
rials of ﬁrst-line HDC for measurable metastases
35], bone-only disease [35], and oligometastases [36].
hese trials were approved by the University of Col-
rado Cancer Center Protocol Review Committee
nd the Institutional Review Board. All patients gave
ritten, informed consent before study entry. Absence
f resistance to chemotherapy, deﬁned as relapse or
rogression during pretransplantation SDC, was re-
uired in these trials. Patients enrolled in phase I trials
f other HDC combinations were not included in this
eport.
HRPBC patients received HDC within 6 months
f primary deﬁnitive surgery (mastectomy or lumpec-
omy with negative margins). IBC patients received c
16reoperative SDC, followed by surgery and HDC.
on-IBC patients received 4 to 6 cycles of doxorubi-
in-containing SDC before HDC. MBC patients were
ot allowed more than 1 conventional chemotherapy
egimen for metastatic disease before HDC. Patients
ith limited (5%) histologic BM involvement were
llowed enrollment in the trial for oligometastatic
isease.
Protocols required adequate visceral organ func-
ion, as described previously [32-34,36]. Pretransplan-
ation staging tests were computed tomographic scans
f the head, chest, abdomen, and pelvis; a bone scan;
nd bilateral BM biopsies. All patients underwent mo-
ilization with G-CSF (10 g/kg/d for 5 days), with
pheresis starting on the ﬁfth mobilization day, and
ryopreservation of the stem cell product, as previ-
usly described [37]. Seventy-nine MBC patients had
heir hematopoietic fractions CD34-selected [37].
DC consisted of cyclophosphamide (5625 mg/m2),
isplatin (165 mg/m2), and carmustine (600 mg/m2).
his was followed by stem cell infusion on days 1 to
1 or on day 1 for patients who received unselected
nd CD34-selected grafts, respectively; administration
f G-CSF at 5 g/kg/d from day 1 until the third
ay with an absolute neutrophil count5000/L; and
ther supportive measures [32-34,36].
Posttransplantation treatment included radiother-
py to locoregional sites (HRPBC) or to amenable
etastases (MBC) upon platelet recovery. Hormone
herapy was prescribed for 5 years to patients with
strogen receptor (ER)–positive or progesterone re-
eptor (PR)–positive tumors. Bisphosphonates were
dministered to most patients with widespread bone
isease. Trastuzumab was not available for clinical use
uring these trials.
CC Assay for Tumor Cell Detection
Prospective ICC of the apheresis products of pa-
ients enrolled in the trials was performed as previ-
usly described [4]. Our assay used monoclonal anti-
odies that targeted cytokeratins (260F9, 520C9, and
17G5), as well as the monoclonal antibody BrE-3,
hich reacts with an epitope of a high-molecular-
eight mucinlike component of the human milk fat
lobule [38]. Prior studies with BrE-3 revealed strong
abeling of breast cancer cells and no labeling of lym-
hocytes or normal BM cells.
As we previously described, the analysis of at least
0 cytospin slides per patient gave a 98% probability
f detecting 4 tumor cells per million mononuclear
ells in PBPC suspensions [4]. Tumor cells were iden-
iﬁed by the dual criteria of immunolabeling and cy-
ological atypia, which consists of 1 or more of the
ollowing: cell clustering; a high nuclear/cytoplasmic
atio; large cell size; large, distinct, and multiple nu-
leoli; and granular nuclear chromatin. Tumor immu-
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Bolabeling on cell membranes was intense. In a few
ases, cross-staining of normal cells was detected, in-
luding plasma cells (which could be strongly reac-
ive), peripheral blood monocytes and granulocytes
which exhibited weak granular membranous or cyto-
lasmic staining), and normal keratinocytes, which
ere occasionally found as a consequence of the bi-
psy procedure. The level of background cross-stain-
ng was low, and in virtually all cases, the cross-stain-
ng was distinguished from tumor cells by the
ombination of staining pattern and cytologic fea-
ures. This assay presents a level of sensitivity (average
f 1 tumor cell per million normal cells) that is similar
o that of PCR, with the added advantage of higher
peciﬁcity, because tumor cells could be directly visu-
lized under the microscope. The apheresis product
as considered positive for OTCs if at least 1 cell with
umor morphology stained positively for any of the
ntibodies tested.
tatistical Methods
Correlations between categorical and continuous
ariables were assessed by using the 2 or Fisher exact
est and the Student t test, respectively. EFS was
eﬁned as the time from study entry to documented
elapse or progression or to death without relapse. OS
as deﬁned as the time from study entry to death from
ny cause. All survival times were analyzed by using
he Kaplan-Meier method [39]. The log-rank test was
sed to study the correlation of potential prognostic
ariables with survival times [40]. Unless mentioned
therwise, the median values of the continuous vari-
bles were chosen as cutoffs. Associations between
ontinuous variables were assessed with the Spearman
orrelation test.
Multivariate proportional hazard Cox regression
odels [41] for EFS or OS included patient- or tu-
or-related variables that we previously identiﬁed as
ndependent predictors. In the HRPBC group, these
ere pathologic tumor size, ER/PR, nodal ratio (No.
ositive axillary nodes/No. dissected nodes), and
ER2 [42,43]. The following scoring system was con-
tructed with the 3 clinical variables:
core  nodal ratio 3.05 tumor size 0.15
 ER/PR 1.1
In this formula, size is entered in centimeters, and
R/PR is assigned 0 if negative and 1 if positive.
cores 2.41 and 2.41 are associated with poor and
ood prognosis, respectively [42].
In MBC patients, we previously reported HER2,
he primary nodal ratio, ER/PR, disease status at
ransplantation (complete response/no evidence of
isease versus nonevaluable disease versus partial re-
ission/stable disease), and number of tumor sites asndependent prognostic factors [35,44]. The signiﬁ- w
B&MTance of the overall model was evaluated with the
ikelihood ratio test. Individual coefﬁcients were
ested by using the Wald test. The proportionality
ssumption for all variables was assessed with Kaplan-
eier curves. All P values presented are 2 tailed.
ESULTS
A total of 470 patients (264 with HRPBC and 206
ith MBC) were prospectively enrolled on the afore-
entioned trials, whose long-term results have been
eported elsewhere [33,35]. Twenty-ﬁve patients (14
ith HRPBC and 11 with MBC; 5.3%) who died from
irect HDC-related complications were excluded
rom this prognostic analysis. Of the remaining pa-
ients, 242 HRPBC (Table 1) and 111 MBC patients
Table 2) primarily underwent apheresis of PBPCs,
nd they constitute the subjects of this report. Their
edian follow-up times were 7.1 years (range, 1.5-11
ears) and 8 years (range, 2-11 years), respectively.
TCs were detected in the apheresis products of 34
atients (9.7%): 16 (6.6%) with HRPBC and 18
16.2%) with MBC (P 	 .005). Among these patients,
he median frequency of OTCs was 9 in 106 cells
range, 1-30) in HRPBC and 3 in 106 cells (range,
-370) in MBC (P 	 .35).
Among HRPBC patients, the distribution of
ome, but not all, prognostic features varied between
he OTC and OTC subgroups (Table 3). There
able 1. Demographics of HRPBC Patients (n 	 242)
Variable Data
ge, y, median (range) 46 (25-711)
umor size (n  232) (cm)
<2 64 (28%)
2-5 98 (42%)
>5 70 (30%)
BC 43 (18%)
R/PR (n  235)
Negative 95 (40%)
Positive 140 (60%)
ER2 (n  231)
Negative 131 (57%)
Positive 100 (43%)
o. of positive nodes (n  233)
0-3 15 (6%)
4-9 100 (43%)
10-20 92 (39%)
>20 26 (12%)
o. of dissected nodes, median (range) 18 (2-46)
odal ratio, median (range)* 0.54 (0-1)
redictive score (n  233) [42]†
Low 173 (74%)
High 60 (26%)
Nodal ratio 	 No. positive nodes/No. dissected nodes.
Predictive score 	 (nodal ratio 
 3.05)  (tumor size 
 0.15) 
ER/PR 
 1.1; scores 2.41: high; scores 2.41: low.as a higher percentage of patients with a high score
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41842] (poorer prognosis) in the OTC group (56%
ersus 24%, respectively; P 	 .004). Patients with
TC products had larger primary tumors (5.5 versus
.9 cm, respectively; P 	 .02) and a trend for a higher
odal ratio (0.66 versus 0.55, respectively; P	 .09). In
ontrast, there were no signiﬁcant differences in the
bsolute numbers of involved nodes (P 	 .37), hor-
one receptors (P 	 1.0), or HER2 status (P 	 .18)
etween groups.
In the MBC group, disease status at transplanta-
ion correlated with risk of contamination of the
pheresis product (Table 4). The percentage of pa-
ients in complete remission or with no evidence of
isease who received an OTC PBPC apheresis prod-
ct was twice that of those who received an OTC
roduct (34.4% versus 16.6%; P 	 .02). Histologic
M involvement was also associated with OTCs in the
pheresis products. Patients with positive BM had a
8.5% risk of OTC products, compared with 8.7%
or patients with negative BM examinations (P 	
005). In contrast, there were no signiﬁcant differences
etween the OTC and OTC subgroups as far as
he number of metastatic sites (P 	 .24), the speciﬁc
ocation of metastases (P 	 .75), the length of prior
isease-free intervals (P 	 .4), exposure to previous
djuvant chemotherapy (P 	 .16), primary nodal ratio
P 	 .35), hormone receptors (P 	 .94), or HER2
tatus (P 	 .35).
nalysis of the Number of Aphereses
The number of apheresis procedures per patient
id not differ signiﬁcantly between HRPBC andMBC
atients (median of 3 in each group; P	 .4). Nineteen
ercent of patients underwent 5 aphereses in each
roup.
The frequency of patients with OTC cells did
ot differ signiﬁcantly depending on the number of
phereses among patients with HRPBC (P 	 .8) or
BC (P 	 .8) or in the entire group (P 	 .7). After
roups were established, the incidences of OTC
roducts among patients with 1 to 2, 3 to 4, or 5
phereses were 3.6%, 5.6%, and 6.6%, respectively
P 	 .8), in the HRPBC group and were 21%, 17.6%,
nd 18.8%, respectively, in the MBC group (P 	 .9).
C (n 	 16) and OTC (n 	 226) Apheresis Products
e Nodes,
SD)
Nodal Ratio,
Mean (SD)* ER/PR† HER2
25) 0.66 (0.25) 37.5% 26.7%
5) 0.55 (0.25) 37.5% 44.2%
.09 1.0 .18able 2. Demographics of MBC Patients (n 	 111)
Variable Data
ge, y, median (range) 48 (26-65)
rimary No. positive nodes (n  106)
0 31 (29%)
1-3 25 (23.5%)
4-9 21 (20%)
>10 24 (22.5%)
odal ratio, median (range) 0.13 (0-1)
umor grade (n  75)
1-2 37 (49%)
3 38 (51%)
R/PR (n  104)
Negative 19 (18%)
Positive 85 (51%)
ER2 (n  96)
Negative 65 (68%)
Positive 31 (32%)
rior adjuvant chemotherapy
No 34 (30%)
Yes 77 (70%)
DXR-containing 40
Non–DXR-containing 37
rior tamoxifen
No 52 (47%)
Yes 59 (53%)
isease-free interval, mo, median (range) 25 (0-194)
o. of metastatic sites
1 34 (30%)
1-5 39 (35%)
>5 38 (34%)
M disease
Yes 42 (38%)
No 69 (62%)
ther tumor sites
Bone 67
Soft tissue 26
Visceral 32
tatus at transplantation
CR/NED 22 (20%)
Bone only 54 (49%)
Single lesion 16
Multiple lesions 38
PR 12 (11%)
PR* 5 (5%)
SD 18 (16%)
D34 selection
Yes 46 (41.5%)
No 65 (58.5%)
R indicates estrogen receptor; PR, progesterone receptor; DXR,
doxorubicin; CR, complete remission; PR, partial remission;
NED, no evidence of disease; PR*, partial remission in measur-
able disease, in addition to bone lesions; BM, bone marrow; SD,
stable disease.able 3. Distribution of Prognostic Features among HRPBC Patients with OT
Variable High Score†
Tumor Size,
Mean (SD)
No. Positiv
Mean (
TC 56% 5.5 (3.6) 9.3 (0.
TC 24% 3.9 (2.6) 11 (7.
value .004 .02 .37
Nodal ratio 	 No. positive nodes/No. dissected nodes.

 1.1; scores 2.41: high; scores 2.41: low.
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Bnivariate Prognostic Analyses
In the HRPBC group, EFS was worse in the group
ith OTC products (44% EFS rate; median EFS,
.9 years) than in the group with OTC products
73% EFS rate; median EFS not reached; P 	 .007;
igure 1A). The OTC group had a worse OS (44%
S rate; median OS, 2.5 years) than the OTC group
77% OS rate; median OS not reached; P 	 .002;
igure 1B).
In the MBC group, EFS was worse in the group
ith OTC products (5.5% EFS rate; median EFS,
0 months) than those with OTC products (30%
FS rate; median EFS, 22 months; P 	 .04; Figure
A). The OS differences between the OTC group
28% OS rate; median OS, 2.5 years) and the OTC
roup (40% OS rate; median OS, 3.5 years) did not
each statistical signiﬁcance (P 	 .2; Figure 2B).
Among patients with contaminated products, we
ould not detect differences in outcome on the basis
f the number of OTC cells in the product. In
RPBC, there was no difference in EFS (P 	 .4) or
S (P 	 .95) between patients with a high (8.5/106)
nd low (8.5/106) number of OTCs. Likewise, no
ifferences in EFS (P 	 .66) or OS (P 	 .9) were

able 4. Distribution of Prognostic Features among MBC Patients with
Variable Status at HDC
BM
Examination
No. Tumor
Sites, Mean
(SD) Loca
TC
CR/NED 16.6%
61.1%  5 (3.3)
Bone/BM
N/E 27.8% Visceral
PR/SD 55.5% Soft tissu
TC
CR/NED 34.4%
32.2%  4 (3.1)
Bone/BM
N/E 40.8% Visceral
PR/SD 24.7% Soft tissu
value .02 .01 .24 .7
ED indicates no evidence of disease; PR, partial remission; SD, st
evaluable.Figure 1. Differences in the outcome of OTC (n 	 16) and OTC (n
B&MToted in MBC patients between those with a high
3/106) and low (3/106) number of OTCs.
Subset analyses of MBC patients included sub-
roups with positive or negative BM examinations and
hose receiving a CD34-selected or an unselected
BPC graft (Table 5). In all 4 subsets, there was a
rend for improved outcome in progression-free sur-
ival for patients with OTC compared with OTC
roducts. In contrast, results of OS comparisons were
ot signiﬁcant across the 4 subsets.
ultivariate Analyses
Multivariate models in HRPBC included the pres-
nce of tumor cells in the graft, along with the nodal
atio, tumor size, hormone receptors, and HER2, all
f which were previously identiﬁed as independent
redictors in this population (Table 6) [42,43]. The
resence of OTC cells in the apheresis product was
ndependently associated with EFS (hazard ratio, 4.0;
	 .0003) and OS (hazard ratio, 3.5; P 	 .002). In
ontrast, in the MBC group, the prognostic effect of
TCs on EFS was not independent of other known
redictors [35], such as HER2, nodal ratio, hormone
(n 	 18) and OTC (n 	 93) Apheresis Products
Prior DFI,
mo, Mean
(SD)
Prior Adjuvant
Chemotherapy ER/PR HER2
Primary
Nodal Ratio,
Mean (SD)
27.9 (22) 83% 16.7% 45% 0.29 (0.30)
36.2 (41) 66.6% 18.7% 42% 0.30 (0.30)
.4 .16 .94 .35 .35
ease; DFI, disease-free interval; CR, complete remission; N/E, notOTC
tion
50%
33.3%
e 16.6%
47%
28%
e 25%
5
able dis	 226) HRPBC patients. A, EFS (P 	 .007); B, OS (P 	 .002).
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4eceptors, status at transplantation, or number of met-
static sites (Table 7).
ISCUSSION
The long-term results of our prospective ICC
nalysis of apheresis products of 353 patients with
dvanced breast cancer undergoing uniform PBPC
obilization with G-CSF and receiving identical
DC show an independent adverse prognostic effect
f OTCs in our population of 242 patients with
RPBC. This is the largest study of OTCs in this
opulation reported to date (Table 8).
Our results provide indirect evidence that occult
ontaminating tumor cells are associated with recur-
ence after HDC for HRPBC. Direct evidence for a
ontribution of contaminating tumor cells to relapse
fter autografting has been shown in neuroblastoma
45] and in acute and chronic myelogenous leukemia
46] by using gene-marking technology. Gribben et al.
47] reported that patients with follicular lymphoma
hose BM harvest products were purged to PCR
egativity had an improved outcome compared with
hose whose stem cell products remained PCR posi-
ive after purging.
In contrast, among patients with MBC, OTCs
ere associated with worse EFS, but not indepen-
ently of other known prognostic variables, and OS
Figure 2. Differences in the outcome of OTC (n 	 18) and
able 5. Subset Analyses in the MBC Group
Variable
EFS Rates
OTC OTC
M (n  42) 0% 23%
M (n  69) 16.7% 33%
D34 selected (n  38) 0% 16.7%
nselected (n  73) 10% 36.5%20omparisons did not reach statistical signiﬁcance. Our
bservations in this group are consistent with those
rom Pecora et al. [30], who observed an adverse effect
f OTCs in univariate, but not multivariate, analyses
f their MBC patients (Table 8).
The potential role of contaminating tumor cells in
elapse in MBC remains unclear. Most posttransplan-
ation relapses in this setting occur in sites of prior
ulk disease. This suggests an insufﬁcient cytoreduc-
ive capacity of HDC rather than a direct effect of
umor cells contaminating the graft. Taken together,
he results of our analysis and other prior analyses
uggest that the contaminating tumor burden in MBC
ay be a marker of widespread micrometastatic dis-
ase rather than a direct cause of recurrence after
ransplantation.
It has been speculated that there might be a
hreshold level of tumor contamination to cause re-
urrence [22]. Detection of a number of tumor cells
bove a hypothetical threshold might reﬂect their pro-
iferative capacity, in contrast to that of nonclonogenic
ells shed from the primary tumor and lodged in the
M. Alternatively, there could be intrinsic biological
ifferences between ICC-detected OTCs, irrespective
f their number, and clonogenic cells. In support of
he threshold burden hypothesis are in vitro cultures
f contaminating OTCs that demonstrate their clo-
ogenic capacity [22,48]. However, we could not de-
(n 	 93) MBC patients. A, EFS (P 	 .04); B, OS (P 	 .2).
OS Rates
P Value OTC OTC P Value
.08 33% 30% .50
.40 16.7% 44% .20
.20 37.5% 33% .60
.10 20% 43% .20
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Bect an effect of the number of OTCs among patients
ith contaminated products in our series. Evidence of
n vivo clonogenicity and direct contribution to re-
apse of contaminating tumor cells can come only
rom gene-marking studies or from randomized pro-
pective trials testing purging strategies.
Our observations in HRPBC patients support the
nvestigation of in vitro or in vivo purging methods in
his population. In vitro negative purging uses drugs
r monoclonal antibodies that target tumor cells.
harmacologic purging achieves 2.5-log tumor cell
epletion on average, albeit with a marked engraft-
ent delay [49]. Studies using immunomagnetic purg-
ng have shown a mean 3-log depletion of cancer cells
ith no obvious prolongation of the engraftment
imes [50]. Both procedures combined result in ap-
roximately 4.5-log tumor cell depletion [51], at the
xpense of substantial engraftment delays [52]. In vitro
ositive selection targets the CD34 antigen, which is
xpressed on 0.5% to 3% of normal BM cells, includ-
ng both the committed and, probably, the long-term
econstituting progenitor cells. The CD34 antigen
oes not seem to be expressed on breast cancer cells
53]. Shpall et al. [37] demonstrated an average 2-log
umor cell depletion with no apparent delays in he-
atopoietic recovery with the use of CD34 selection
n 44 breast cancer patients. These observations were
onﬁrmed in randomized studies [54,55]. Subse-
uently, Yanovich et al. [56] randomized 92 HRPBC
atients to receive HDC with CD34-selected or un-
elected PBPCs. No short-term EFS or OS differ-
nces were noticed in this small trial. Because most
atients with contaminated products still have detect-
ble cancer cells present in their stem cell grafts after
able 6. Multivariate Analyses: HRPBC Patients
Variable
EFS
Hazard Ratio (95% CI)
umor cells in graft (yes vs. no) 4.0 (1.8-8.6)
ER2 (positive vs. negative) 2.0 (1.2-3.4)
odal ratio (>0.75 vs. <0.75) 2.3 (1.4-3.8)
R/PR (positive vs. negative) 0.5 (0.3-0.8)
umor size (>5 vs. <2 cm) 1.4 (1.01-1.9)
I indicates conﬁdence interval.
able 7. Multivariate Analyses: MBC Patients
Variable Hazar
ER2 (positive vs. negative)
odal ratio (>0.15 vs. <0.15)
R/PR (negative vs. positive)
tatus at transplantation (PR/SD vs. N/E vs. CR/NED)
o. sites (>1 vs. 1)
umor cells in graft (yes vs. no)evaluable.
B&MTD34 selection, maximally effective in vitro purging
ay require a combination of positive- and negative-
election procedures [57].
Additionally, optimal purging might require in
ivo depletion of tumor in the BM before PBPC
ollection. Breast cancer cells metastasizing in the BM
resent a low proliferation rate, with low or no ex-
ression of proliferation markers such as Ki-67 and
120 [58]. Their quiescent state could confer on them
low sensitivity to chemotherapy. It has been ob-
erved that SDC [59] and even HDC [60,61] often
ails to eliminate BM micrometastases. These obser-
ations suggest a limited capacity of chemotherapy to
urge breast cancer in vivo, in contrast to its capacity
o cytoreduce extramedullary disease. Exploring alter-
ative approaches, such as immune-based therapies
62], may prove worthwhile.
This report constitutes an analysis of the effect of
TCs within the different patient subsets and is not a
irect comparison of outcomes in the MBC groups
eceiving a CD34-selected or an unselected PBPC
roduct. Such a comparison would probably not be
eaningful in view of the major baseline differences
etween groups. Within the MBC group that under-
ent CD34 selection, this procedure did not seem to
brogate the negative effect of OTCs. Although more
owerful purging methods may improve results in
BC patients with an OTC product, CD34 selec-
ion causes a greater than 2-log lymphocyte depletion
f the graft [63], which might be deleterious in control
f posttransplantation minimal residual disease. We
nd others have shown that pretransplantation im-
une status [64] or early posttransplantation lympho-
yte recovery [35,65] correlates with outcome in MBC
OS
P Value Hazard Ratio (95% CI) P Value
.0003 3.5 (1.5-7.8) .002
.009 2.1 (1.2-3.6) .006
.002 2.1 (1.3-3.5) .004
.008 0.4 (0.2-0.7) .001
.04 1.5 (1.1-2.2) .01
EFS OS
(95% CI) P Value Hazard Ratio (95% CI) P Value
-5.5) .01 3.9 (1.9-7.9) .001
-3) .006 2.2 (1.2-3.8) .005
-0.6) .006 0.37 (0.2-0.7) .001
-2.2) .03 1.5 (1.4-1.6) .04
-4.7) .003 2.0 (1.02-4) .03
-2.1) .5 1.1 (0.6-2.2) .60d Ratio
2.8 (1.4
1.9 (1.3
0.4 (0.2
1.5 (1.1
2.5 (1.3
1.2 (0.6
I indicates conﬁdence interval; PR, partial remission; SD, stable disease; CR, complete remission; NED, no evidence of disease; N/E, not421
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4atients. Thus, if OTCs in this population merely
epresent a marker of widespread micrometastases,
trategies to enhance the patients’ immune systems
ight be more appropriate.
In this study we did not attempt to correlate the
ontamination of BM with that of the apheresis prod-
cts. Previously, Franklin et al. [66] observed 8.3%
nd 4.5% incidences of contamination of BM and
pheresis products, respectively, in 203 patients with
tage II to IV disease by using the same ICC assay as
n this report. Pecora et al. [30] analyzed 535 stage IV
atients with an ICC technique of similar sensitivity
nd reported that 26.3% and 20.6% of them had
ontaminating tumor cells in their BM and apheresis
roducts, respectively. The different incidences of tu-
or contamination in both studies may be due to the
ifferent tumor stages of their populations.
All patients in this report had their stem cells
niformly mobilized with G-CSF alone. The effect of
hemotherapy mobilization on OTC involvement of
BPC collections remains unclear [67]. Brugger et al.
68] reported an increased detection of circulating
umor cells after stem cell mobilization with chemo-
herapy and G-CSF compared with steady-state stud-
es performed on the same patients. These authors
etected tumor cells after mobilization in 20% of
atients with no detectable tumor cells in PB before
obilization. In contrast, Passos-Coelho et al. [69] did
ot observe an increased incidence of OTCs in pe-
ipheral blood after stem cell mobilization with cyclo-
hosphamide and GM-CSF or G-CSF alone [70].
In contrast with observations by others that sug-
ested a higher incidence of contaminated products
ith more apheresis [27,30], we did not observe an
ncreased risk of OTCs with an increasing number of
pheresis procedures. The reasons for this discrepancy
able 8. Representative Prognostic Studies (n  50) of ICC in the Aph
Study n
Median
FU (y)
% Patients
with OTC
Cells OTC
RPBC
Weaver [27] 114 1.5 14% 69%
Viret [29] 94 4 8.5% 86%
Solano [24] 51 4.6 27% 75%
Current study 242 7.1 7% 76.5%
BC
Pecora [30] 403 NR 21% NR (median 40
days)
Weaver [27] 90 1.5 24% NR (69% relaps
rate)
Cooper [31] 57 NR 40% 12%
Current study 111 8 16% 30%
R indicates not reported; NS, not signiﬁcant (P value not report
Conﬁrmed in multivariate analyses.
Signiﬁcant in univariate, but not multivariate, analyses.re unclear. Although no differences were apparent in
22he number of aphereses performed (median of 3),
here were potentially important differences in the
obilization techniques; we used only G-CSF in our
tudy, compared with cytokine (G-CSF or granulo-
yte-macrophage colony-stimulating factor) alone or
ytokine plus single or multiagent chemotherapy in
he other reports [27,30].
In conclusion, we observed a powerful and inde-
endent adverse effect of OTCs, detected by ICC, in
he apheresis products of HRPBC patients, suggesting
possible role of contaminating cells in relapse. In
ontrast, our observations in MBC patients did not
upport a direct contribution of contaminating cells to
osttransplantation disease recurrence in this popula-
ion.
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